# Synergistic anti-tumor effect of dichloroacetate and ivermectin

Source: https://onco.cc/key-papers/paper-ishiguro-dichloroacetate-ivermectin-cureus-2022/  
OnCo record `paper-ishiguro-dichloroacetate-ivermectin-cureus-2022` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Three patients treated at a private clinic with dichloroacetate, omeprazole, tamoxifen and ivermectin were reported to have relief of symptoms; there was no control, no measured tumour response and no follow-up study.

## Summary

The authors, who had earlier proposed that dichloroacetate, omeprazole and tamoxifen block cancer progression by reducing lactic acid production, present three patients in whom adding ivermectin was said to have 'dramatically relieved' the symptoms of cancer and sarcoma progression (Ishiguro case series 2022). The report describes symptom relief rather than tumour measurements (Ishiguro case series 2022).

## Fields

- Kind: Key paper
- Last checked: 2026-09-24
- Journal: Cureus
- Year: 2022
- DOI: 10.7759/cureus.21884
- Authors: Ishiguro T, Ishiguro RH, Ishiguro M, Toki A, Terunuma H.
- Findings: Three patients; symptom relief reported; no objective response measured.
- What it means: An anecdote from the clinic that prescribed the regimen; it cannot show benefit and has not led to a trial.
- Caveats: No control group, no tumour measurements, authors treated the patients they report on.

## Sources

- Ishiguro case series 2022: https://doi.org/10.7759/cureus.21884
- PubMed: https://pubmed.ncbi.nlm.nih.gov/35265417/

## Connected records

- drugs: [Ivermectin](https://onco.cc/drugs/ivermectin/)

---
JSON: https://onco.cc/api/v1/entities/paper-ishiguro-dichloroacetate-ivermectin-cureus-2022.json